Strasbourg-based preclinical CRO NovAliX, specializing in drug discovery services, received an investment from Bruker. The funds will accelerate NovAliX’s growth, particularly in Europe and the U.S. The partnership will advance drug discovery by combining NovAliX’s biophysics expertise with Bruker’s focus on structural biology and therapeutic mechanisms.